Bristol Medical School, Faculty of Health Sciences, University of Bristol, Bristol, UK
Keenan Research Centre for Biomedical Science, St Michael's Hospital, Toronto, Ontario, Canada.
BMJ Open. 2019 Oct 28;9(10):e030318. doi: 10.1136/bmjopen-2019-030318.
Sex differences in respiratory physiology and predilection for developing chronic obstructive pulmonary disease (COPD) have been documented, suggesting that female sex hormones may influence pathogenesis. We investigated whether aspects of female reproductive health might play a role in risk of COPD among women.
Population-based prospective cohort study.
UK Biobank recruited across 22 centres in the UK between 2006 to 2010.
We examined a range of female reproductive health indicators in relation to risk of COPD-related hospitalisation/death (n=271 271) using Cox proportional hazards regression; and lung function (n=273 441) using linear regression.
Parity >3 was associated with greater risk of COPD-related hospitalisation/death (adjusted HR 1.45; 95% CI: 1.16 to 1.82) and lower forced expiratory volume at 1 second/forced vital capacity ratio (FEV/FVC) (adjusted mean difference -0.06; 95% CI: -0.07 to 0.04). Any oral contraception use was associated with lower risk of COPD-related hospitalisation/death (adjusted HR 0.85; 95% CI: 0.74 to 0.97) and greater FEV/FVC (adjusted mean difference 0.01; 95% CI: 0.003 to 0.03). Late menarche (age >15) and early menopause (age <47) were also associated with greater risk of COPD-related hospitalisation/death (but not lung function), while endometriosis was associated with greater FEV/FVC (not COPD-related hospitalisation/death). Early menarche (age <12 years) was associated with lower FEV/FVC (but not COPD hospitalisation/death). Associations with polycystic ovary syndrome (PCOS) or ovarian cysts, any hormone replacement therapy (HRT) use, hysterectomy-alone and both hysterectomy and bilateral oophorectomy were in opposing directions for COPD-related hospitalisation/death (greater risk) and FEV/FVC (positive association).
Multiple female reproductive health indicators across the life course are associated with COPD-related hospitalisation/death and lung function. Further studies are necessary to understand the opposing associations of PCOS/ovarian cysts, HRT and hysterectomy with COPD and objective measures of airway obstruction.
有研究表明,呼吸生理学和慢性阻塞性肺疾病(COPD)发病倾向存在性别差异,这表明女性性激素可能影响发病机制。我们研究了女性生殖健康的各个方面是否可能在女性 COPD 风险中发挥作用。
基于人群的前瞻性队列研究。
英国生物库(UK Biobank)在 2006 年至 2010 年期间在英国的 22 个中心进行招募。
我们使用 Cox 比例风险回归分析了一系列女性生殖健康指标与 COPD 相关住院/死亡风险(n=271271)之间的关系;并使用线性回归分析了这些指标与肺功能(n=273441)之间的关系。
产次>3 与 COPD 相关的住院/死亡风险增加相关(调整后的 HR 1.45;95%CI:1.16 至 1.82),用力呼气量/用力肺活量比值(FEV/FVC)降低(调整后的平均差异-0.06;95%CI:-0.07 至 0.04)。任何口服避孕药的使用都与 COPD 相关的住院/死亡风险降低相关(调整后的 HR 0.85;95%CI:0.74 至 0.97),FEV/FVC 更高(调整后的平均差异 0.01;95%CI:0.003 至 0.03)。初潮晚(年龄>15 岁)和绝经早(年龄<47 岁)也与 COPD 相关的住院/死亡风险增加相关(但与肺功能无关),而子宫内膜异位症与 FEV/FVC 更高(与 COPD 相关的住院/死亡无关)。初潮早(年龄<12 岁)与 FEV/FVC 降低(但与 COPD 住院/死亡无关)相关。多囊卵巢综合征(PCOS)或卵巢囊肿、任何激素替代疗法(HRT)使用、单纯子宫切除术和子宫切除术加双侧卵巢切除术与 COPD 相关的住院/死亡(更高的风险)和 FEV/FVC(正相关)的相关性呈相反方向。
一生中多个女性生殖健康指标与 COPD 相关的住院/死亡和肺功能有关。需要进一步研究以了解 PCOS/卵巢囊肿、HRT 和子宫切除术与 COPD 以及气道阻塞的客观测量结果之间相反的关联。